ClinicalTrials.gg
Not yet recruitingNCT07849361TEAM-ICUpdated Oct 5, 2026

Feasibility Study on the Implementation of a Program to Facilitate the Return Home of Patients With Heart Failure Following Hospitalization, Led by a Coordinated Multidisciplinary Team Based on the "Team-based Care" Model

An interventional study of Intervention Arm - TEAM-IC in Heart Failure, sponsored by Sant'Innovation. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Sant'Innovation · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 5, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.

Planned enrollment
179th of 282
100 · median 196
Started
2026
with 26 others
No phase
176 of 448
47 open now
Primary completion
2027-12
later than 65 of 115 live
Registered
447th of 448
by date

Among the 448 studies in Heart Failure with a site in France, this one is the 179th largest by planned enrollment of the 282 interventional ones that give a count, is one of 27 that started in 2026, is one of 176 with no phase, reaches primary completion later than 65 of the 115 other live ones, and was the 447th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Heart Failure with a site in France, or all of them as a file.
02

Study summary

Heart failure is a common heart condition that often leads to hospital stays and repeat readmissions. When patients leave the hospital, coordinating patient care between the hospital and the local healthcare team (family doctor, nurses, cardiologist) can be difficult, and gaps in this coordination can lead to complications or unnecessary re-hospitalizations.

This study, called TEAM-IC, tests a new way of organizing the return home after a hospital stay for heart failure. In this new approach, a dedicated "care coordination nurse" based in a local primary care health center works closely with the patient's usual caregivers and with the hospital team to support the patient during the first three months after discharge. This is compared to the existing standard program (PRADO-IC) currently used in France.

Hypothesis: The investigators believe that organizing the return home around a coordinating nurse embedded in a local health center, with support tailored to each patient's level of frailty, will lead to better follow-up and better care for heart failure patients than the current standard program.

Before testing whether this approach actually improves health outcomes in a larger trial, this study first aims to find out whether such a program is realistic and workable in practice, for example, whether patients and healthcare professionals are willing to take part, whether the organization runs smoothly, and whether the study procedures can be followed as planned.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age > 18 years with no upper age limit;
  • Hospitalized for heart failure;
  • Discharge home anticipated within 7 days of enrollment;
  • Signed and dated ;
  • Resident within the GHT Centre Franche-Comté and within a maximum of one hour by road from one of the two enrolling centers.

Exclusion criteria

Exclusion Criteria:

  • Needfor a heart transplant or ventricular assist device;
  • Any severe valvular heart disease that could benefit from surgical intervention during the course of the study;
  • Patients with a of less than 3 months;
  • A person subject to a legal protection measure, involuntary psychiatric care, unable to give consent, to follow instructions, or to comply with follow-up procedures;
  • Any other medical condition that would put the patient at risk or could influence the study results
  • Not affiliated with or not a beneficiary of a French social security scheme;
  • Subject in the exclusion period of another study or listed in the "national register of volunteers" ("fichier national des volontaires");
  • Patient currently enrolled in an ongoing interventional clinical research study on heart failure management (risk of interference);
  • Patient already benefiting from a home discharge program other than the PRADO program.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention Arm - TEAM-IC

    Patients randomized to this arm receive the TEAM-IC pathway following hospitalization for heart failure. Before discharge, a care-pathway support nurse (IAP), based in a resource primary care health center (MSP), assesses frailty (SEGA-A scale), non-adherence risk (SPUR), and quality of life (KCCQ-12), then stratifies the patient into one of three follow-up intensity levels. The patient is registered on a regional care-coordination platform (eTICSS) and offered telemonitoring of weight, blood pressure, and heart failure warning signs. The patient's GP and community nurse are informed, receive personalized recommendations and access to online training modules, and are supported by the IAP for 3 months post-discharge, including help with administrative/social care referrals and a cardiology advanced-practice nurse consultation at 1 month. The GP's role as primary caregiver is not modified; the IAP provides additional coordination support alongside standard care.

    Other: Intervention Arm - TEAM-IC

  • No intervention
    Control Arm - PRADO

    Patients randomized to this arm receive the standard PRADO-IC discharge program managed by the French national health insurance (CPAM), with no TEAM-IC coordination support. Before discharge, the IAP still assesses frailty (SEGA-A), non-adherence risk (SPUR), and quality of life (KCCQ-12), but these results do not trigger any specific follow-up actions in this arm. The patient is offered standard telemonitoring and/or advanced-practice nurse (IPA) follow-up as usually available. Home nursing visits and clinical monitoring follow the usual PRADO-IC protocol for 3 months. At month 3, the study team collects outcome data for comparison with the intervention arm: rehospitalization, non-hospitalized decompensation episodes (EPOF signs), NYHA class, BNP level, mortality, guideline-recommended drug prescriptions, KCCQ score, healthcare utilization, and satisfaction questionnaires from the patient, GP, and community nurse

Interventions

  • OtherIntervention Arm - TEAM-IC

    A 3-month post-discharge care pathway for heart failure patients, coordinated by a dedicated care-pathway support nurse (IAP) based in a resource primary care health center (MSP), working alongside the patient's own GP and community nurse. Before discharge, the IAP assesses frailty (SEGA-A scale) and non-adherence risk (SPUR), then stratifies patients into 3 follow-up intensity levels. The IAP registers patients on a regional hospital-community coordination platform (eTICSS), offers telemonitoring of weight, blood pressure and heart failure warning signs, and liaises with the hospital's advanced-practice nurse in cardiology. The GP and community nurse receive personalized recommendations, online training modules, and support for administrative and social care referrals. Unlike the PRADO-IC control arm, the intervention adds an upstream frailty/adherence assessment and a primary-care-based coordinating nurse linked directly to the hospital team.

06

What researchers measure

Primary outcomes

  1. Organizational feasibility: proportion of study procedures completed as planned

    Percentage of scheduled study procedures (appointments and data collection visits) carried out as planned in the TEAM-IC care pathway, among all scheduled procedures. As this is a pilot feasibility study, no statistical hypothesis testing is planned; results will be reported descriptively to inform the design of a future full-scale trial.

    Time frame: From discharge to 3 months after discharge

  2. Acceptability: inclusion rate among eligible patients

    Percentage of eligible patients who are included in the study (number of included participants divided by number of eligible patients). The numbers of potentially eligible, eligible, not contacted, refusing, and included patients will be reported in the participant flow chart. Results will be reported descriptively.

    Time frame: At eligibility assessment, during the index hospitalization for heart failure

  3. Protocol adherence: completeness of collected data

    Percentage of expected data items actually collected, among all data items planned by the protocol. Results will be reported descriptively.

    Time frame: From inclusion to 3 months after discharge

  4. Protocol adherence: attrition rate

    Percentage of included participants who leave the study before the end of follow-up, whether through consent withdrawal, non-adherence to the program, or loss to follow-up. Results will be reported descriptively.

    Time frame: From inclusion to 3 months after discharge

  5. Adherence to the projected study timeline: actual versus planned enrollment

    Number of participants actually enrolled, expressed as a percentage of the number planned at the corresponding milestone of the study timeline. Results will be reported descriptively.

    Time frame: At enrollment, during the index hospitalization for heart failure

07

Study locations

1 site
  • MSP " Sant'Innovation " de Palente
    Besançon, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 1,118 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 14 months is below that.

Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Oct 4, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
5 added, 1 removed
What changed in the outcomes
  • AddedOrganizational feasibility: proportion of study procedures completed as plannedTime frame: From discharge to 3 months after discharge
  • AddedAcceptability: inclusion rate among eligible patientsTime frame: At eligibility assessment, during the index hospitalization for heart failure
  • AddedProtocol adherence: completeness of collected dataTime frame: From inclusion to 3 months after discharge
  • AddedProtocol adherence: attrition rateTime frame: From inclusion to 3 months after discharge
  • AddedAdherence to the projected study timeline: actual versus planned enrollmentTime frame: At enrollment, during the index hospitalization for heart failure
  • RemovedOverall feasibility of the TEAM-IC care pathwayTime frame: 3 months
Oct 5, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Oct 5, 2026
    Primary outcomes 5 added, 1 removed
    What changed in the outcomes
    • AddedOrganizational feasibility: proportion of study procedures completed as plannedTime frame: From discharge to 3 months after discharge
    • AddedAcceptability: inclusion rate among eligible patientsTime frame: At eligibility assessment, during the index hospitalization for heart failure
    • AddedProtocol adherence: completeness of collected dataTime frame: From inclusion to 3 months after discharge
    • AddedProtocol adherence: attrition rateTime frame: From inclusion to 3 months after discharge
    • AddedAdherence to the projected study timeline: actual versus planned enrollmentTime frame: At enrollment, during the index hospitalization for heart failure
    • RemovedOverall feasibility of the TEAM-IC care pathwayTime frame: 3 months
    + 1 other change: description
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849361
Lead sponsor
Sant'Innovation
Collaborators
Direction Générale de l'Offre de Soin (DGOS), FeMaSCo-BFC, Agence Régionale de Santé - Bourgogne Franche Comté
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 4, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion